信達生物(01801.HK)第四季度總產品收入約10億元
格隆匯2月2日丨信達生物(01801.HK)宣佈,於2022年第四季度,公司共取得總產品收入約人民幣10億元。第四季度由於全國較廣範圍的新冠疫情的傳播,公司於全國市場的產品銷售和推廣活動整體受到一定程度影響,但同時新產品的持續貢獻及希冉擇(雷莫西尤單抗)於第四季度正式進入市場抵消了部分影響。
公司相信疫情的短期擾動將不影響公司商業化組合和產品銷售的長期增長趨勢。於2023年,公司相信,新冠疫情感染的影響回穩向好後,公司產品銷售活動將逐步恢復正常,產品收入將持續逐年增長。公司商業化管線已擴充至8款產品,預計多款新產品將持續放量,而且另有3款創新候選藥物處於新藥上市申請(NDA)審評階段有望陸續獲批上市。除此之外,公司於日前公佈,達伯舒兩項新增適應症、耐立克新藥及達攸同、達伯華、蘇立信多項新增適應症納入2022年版國家醫保藥品目錄,繼續擴大醫保支付範圍,受益患者羣體不斷擴大。產品的持續放量,市場覆蓋和准入繼續提升以及協同價值日益凸顯,為公司商業化產品組合的持續增長打下堅實基礎。
同時,公司採用更加可持續和精細化的商業管理模式,旨求進一步提升產出和改善效益。公司相信,良好的運營能力和模式,能夠在有效提升銷售規模的同時提高效率和收益,保障實現創新管線的產品價值,實現業務的長期可持續發展,更高效地支撐和落實公司戰略。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.